Abstract: Tremendous advances in therapeutics have drastically extended the life expectancy of many cancer patients, including those with skeletal metastases. However, bone metastases and their treatment can negatively impact bone quality and musculoskeletal health. Bone strength assessment and fracture risk prediction are critically important in guiding clinical treatment decisions. This presentation will describe the clinically translational bioengineering approach undertaken by Dr Whyne and her multidisciplinary research team to studying skeletal metastases and the development and evaluation of minimally invasive technologies to treat bone metastases.
Bio: Dr Whyne is a graduate of Queen’s Mechanical Engineering who has gone on to pursue an academic career in clinically translational musculoskeletal biomedical engineering research.
Dr. Whyne’s lab is focused on translational bioengineering research aimed at better understanding the biomechanics of the musculoskeletal system and developing minimally invasive technology to diagnose and treat musculoskeletal disease and injury. Using an engineering approach, her team uses experimental and numerical methods, including the following:
- in vitro and in vivo testing
- computational modeling
- image analysis
- biomechanical testing
- design and minimally invasive technology development.
Dr. Whyne’s work integrates biomechanical analyses with clinical and basic science investigations of musculoskeletal injury and disease, with a final goal of translating findings into the clinic. Her work is primarily focused in the areas of skeletal metastases, spinal,lower extremity and thin bone biomechanics, image-guided surgery, and fracture fixation and healing.
https://sunnybrook.ca/research/content/?page=sri-groups-obl-about